Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

Innovative work in genetic testing is apparently spelled Innogenetics in any language. The biopharmaceutical company creates genetic, infectious disease, cancer, and neurological tests. Innogenetics' products include tests and genotyping profiles to identify conditions such as cystic fibrosis, HIV, hepatitis C and B, Alzheimer's disease, and human papillomavirus (HPV). In addition to testing, the company provides biological manufacturing services (producing virus strains and proteins) for pharmaceutical firms and research labs. The firm's products are sold through subsidiaries and distributors in about 90 countries. Belgium's Solvay took over control of Innogenetics in 2008.

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

Photopharmica Ltd. discovers and develops photo sensitizers and light sources for medical use in the United Kingdom. The company develops anti-infective agents primarily for dermatology and wound management markets; and medical devices in the fields of orthopedics and periodontal equipment. Its products pipeline includes phenothiazinium photo sensitizers for use as topical therapeutic antimicrobial agents; phenothiazinium photo sensitizers for systemic oncology use; and phthalocyanine photo sensitizers that combine anti-tumor properties with minimal or zero skin photo sensitization. Photopharmica Ltd. was founded in 2001 and is based in Leeds, the United Kingdom.

Shionogi Pharma, Inc. company was founded in 1992 and is headquartered in Atlanta, Georgia. Sciele Pharma Inc. operates as a subsidiary of Shionogi & Co. Ltd. Sciele Pharma Inc., a pharmaceutical company, engages in acquiring, developing, marketing, and selling prescription products for patients primarily in the United States. It offers oral suspensions, tablets, and capsules, as well as products prescribed by the primary care physicians. The company provides cardiovascular and diabetes products that treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 diabetes; pediatrics products, which treat allergies, asthma, cough and cold, and attention deficit and hyperactivity disorders; and products for the health and well-being of women, as well as for mothers and their babies. It develops glycopyrrolate oral solution, a treatment for chronic, moderate-to-severe drooling in pediatric patients.

Streck, Inc. company was founded in 1971 and is based in Omaha, Nebraska. Streck, Inc. develops and manufactures hematology, chemistry, and immunology products for the clinical laboratory in the United States, Japan, and internationally. It offers controls for automated hematology instruments, and hematology controls, reagents, and support products; controls for immunophenotyping by flow cytometry; A1c-Cellular, a blood cellular control product for instruments measuring HbA1c; and UA-Cellular for IQ that provides a thorough evaluation of the iQ instrument's ability to identify and quantify white blood cells, red blood cells, non-squamous epithelial cells, and crystals. The company also provides hematology reagents, which include diluents, lysing agents, enzymatic cleansers, and detergents; quality control devices, including the red spirit thermometers with scales in 1/2-degree increments to monitor refrigerators, freezers, and incubators/room temperatures; and automated erythrocyte sedimentation rate (ESR) analyzers. In addition, it offers technical services.

SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

MDS Pharma Services saves drugmakers time and energy when it comes to drug discovery. The company, a subsidiary of MDS, is a provider of contract research and development services for pharmaceutical and biotechnology companies. Through facilities in the Americas, Asia, and Europe, MDS Pharma Services provides its clients with early-stage clinical research and development services, such as consulting, target discovery, lead optimization, regulatory assistance, and Phase I-phase IIa testing. It employs an international network of scientists that serve as testing investigators. MDS Pharma has been put up for sale by parent company MDS.

BioReliance Corporation company was founded in 1947. Private equity firm Avista Capital Partners controls the company. BioReliance helps biotechnology and pharmaceutical companies suffering from test anxiety. The outsourcing company helps drug developers with contract testing and manufacturing services. With facilities in the UK and the US, BioReliance offers biologics safety testing, manufacturing services, preclinical testing services (such as animal lab diagnostics and toxicology), and clinical trial support. Its manufacturing plants make vaccines, gene therapies, and other kinds of biologics for use in clinical trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.